Director Christopher Ross MacLeod filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of Stock Appreciation Rights in Zomedica Corp. on November 16, 2026.
Key Highlights
- Reporting person: Christopher Ross MacLeod, listed as a Director of Zomedica Corp.
- Security acquired: 1,823,107 Stock Appreciation Rights, acquired on November 16, 2026, with transaction code A (acquired).
- Exercise price: The conversion or exercise price of the Stock Appreciation Right is listed as $0.10.
- Price paid: The price of the derivative security at acquisition is listed as $0.
- Expiration date: The rights are exercisable beginning November 15, 2027, and expire on November 15, 2036.
- Beneficial ownership following transaction: MacLeod directly owns 1,823,107 derivative securities following this transaction.
- Underlying security: The rights are tied to 1,823,107 shares of Zomedica Corp. common stock.
MacLeod's November 2026 Stock Appreciation Right Award at Zomedica Corp.
According to the Form 4 filed with the SEC on November 17, 2026, Christopher Ross MacLeod, a Director of Zomedica Corp. (OTC:ZOMDF), acquired 1,823,107 Stock Appreciation Rights on November 16, 2026. The filing identifies the transaction code as "A," indicating these securities were acquired rather than disposed of. The price of the derivative security at acquisition is reported as $0, while the conversion or exercise price is listed as $0.10.
The filing discloses that the rights become exercisable on November 15, 2027, and carry an expiration date of November 15, 2036, giving them a ten-year term from grant. The underlying security is Zomedica Corp. common stock, with 1,823,107 shares referenced as the amount underlying the rights. Following this transaction, MacLeod is reported to directly and beneficially own 1,823,107 of these derivative securities. The filing does not report any transactions in Table I covering non-derivative securities.
The Form 4 was signed by Christopher MacLeod and dated November 17, 2026. No amendment date is indicated, suggesting this is an original filing. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan.
What Was Disclosed
Zomedica Corp. Director Christopher Ross MacLeod disclosed the acquisition of 1,823,107 Stock Appreciation Rights at an exercise price of $0.10, with no cost at acquisition, exercisable from November 15, 2027, through November 15, 2036, in a Form 4 filed November 17, 2026.



Please wait processing your request...